ReviewReviews in endocrine & metabolic disorders2022
Androgens, aging, and prostate health.
Review in Reviews in endocrine & metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Aging and prostate health: meta-analytic insights into age-related prostatic disorders.Frontiers in oncology · 2026Pooled it
- Structural and proliferative responses of the prostate to abrupt versus tapered discontinuation of dutasteride in short- and long-term treated rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Intervention of Bazi Bushen Capsule on Benign Prostatic Hyperplasia Concomitant with Erectile Dysfunction Induced by Testosterone Supplementation in Spontaneously Hypertensive Rats.Chinese journal of integrative medicine · 2026Article
- Potential Health Benefits of Bee Bread from Stingless Bees on Reproductive Health: A Review.International journal of molecular sciences · 2026Review
- Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.Frontiers in immunology · 2026Review
- Association Between Long-term Use of HJournal of Cancer · 2026Article
- Gut microbes and benign prostatic hyperplasia: the role of dysbiosis.Frontiers in urology · 2026Review
- Identification of programmed cell death associated key genes in benign prostatic hyperplasia and prostate cancer development by integrated bioinformatics analysis and machine learning.Translational andrology and urology · 2025Article
- Identification of genes related to the effects of bicalutamide and zoladex on benign prostatic hyperplasia.Scientific reports · 2025Article
- Global, regional, and national lifetime risks of developing benign prostatic hyperplasia in men aged over 40: a population-based cross-sectional study from 1990 to 2021.Tropical medicine and health · 2025Article
- ISUP grade upgrade prediction after radical prostatectomy: Role of Luteinizing Hormone to Testosterone ratio.BJUI compass · 2025Article
- Incidence of benign prostatic hyperplasia in testicular cancer survivors in the Veteran's affairs health system.World journal of urology · 2025Article
- The causal impact of bioavailable testosterone levels on osteoarthritis: a bidirectional Mendelian randomized study.BMC musculoskeletal disorders · 2025Article
- Prognostic Significance of Ki67 Expression in Prostate Cancer in Nigerians: A Single-Center Study.Cureus · 2025Article
- Review
- Chewable tablets containing rape bee pollen and maca attenuate testosterone propionate-induced benign prostatic hyperplasia in Sprague-Dawley rats by regulating the gut microbiota and modulating the IL-6/JAK2/STAT3 signaling pathway.Frontiers in microbiology · 2025Article
- Portulaca oleracea Extract Ameliorates Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Male Sprague-Dawley Rats.Veterinary medicine and science · 2025Article
- Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights.Research and reports in urology · 2025Review
- Prostatic androgen receptor signaling shows an age-related and lobe-specific alteration in mice.Scientific reports · 2024Article
- Elevated periprostatic androgens, sneaky testosterone and its implications.Nature reviews. Urology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to late onset hypogonadism (LOH), there is an increased usage of testosterone replacement therapy (TRT) in the aging male population. Since prostate is a target organ for androgens and anti-androgenic strategies are used to treat and palliate benign prostate hyperplasia (BPH) and prostate cancer (PC), the prevalence of both increases with age, the possible influence of TRT on prostate health becomes highly relevant. The present review summarizes existing data on the associations between endogenous hormone concentrations and prostate growth and concludes that circulating concentrations of androgens do not appear to be associated with the risks of development of BPH or initiation or progression of PC. The explanation for these findings relates to an apparent insensitivity of prostatic tissue to changes of testosterone concentrations within the physiological range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.